26.65
Precedente Chiudi:
$25.48
Aprire:
$25.36
Volume 24 ore:
76,517
Relative Volume:
0.83
Capitalizzazione di mercato:
$249.66M
Reddito:
-
Utile/perdita netta:
$-81.17M
Rapporto P/E:
-2.6297
EPS:
-10.1344
Flusso di cassa netto:
$-82.84M
1 W Prestazione:
-9.11%
1M Prestazione:
-28.55%
6M Prestazione:
-40.90%
1 anno Prestazione:
-46.69%
Korro Bio Inc Stock (KRRO) Company Profile
Nome
Korro Bio Inc
Settore
Industria
Telefono
617-468-1999
Indirizzo
60 FIRST STREET, CAMBRIDGE
Confronta KRRO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KRRO
Korro Bio Inc
|
26.65 | 249.66M | 0 | -81.17M | -82.84M | -10.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-10 | Iniziato | Oppenheimer | Outperform |
2024-10-21 | Iniziato | Raymond James | Strong Buy |
2024-08-14 | Iniziato | William Blair | Outperform |
2024-03-28 | Reiterato | H.C. Wainwright | Buy |
2024-02-27 | Iniziato | BMO Capital Markets | Outperform |
2023-12-04 | Iniziato | H.C. Wainwright | Buy |
2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
2023-11-10 | Iniziato | Piper Sandler | Overweight |
2023-02-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2023-02-13 | Downgrade | Cowen | Outperform → Market Perform |
2021-09-22 | Downgrade | Goldman | Buy → Neutral |
2021-01-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
2020-12-22 | Iniziato | B. Riley Securities | Buy |
2020-07-14 | Iniziato | Oppenheimer | Outperform |
2020-05-18 | Downgrade | JP Morgan | Overweight → Neutral |
2019-10-28 | Iniziato | Cowen | Outperform |
2019-10-28 | Iniziato | Goldman | Buy |
2019-10-28 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Korro Bio Inc Borsa (KRRO) Ultime notizie
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World
KRRO stock touches 52-week low at $28.71 amid market challenges - Investing.com Nigeria
Korro Bio CFO takes medical leave, interim officers appointed - MSN
Korro Bio CFO takes medical leave, interim officers appointed By Investing.com - Investing.com Nigeria
Korro Bio Appoints Interim CFO Amid Medical Leave - TipRanks
Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting Officer -February 11, 2025 at 04:05 pm EST - Marketscreener.com
KRRO stock touches 52-week low at $29.8 amid yearly slump - Investing.com
AllianceBernstein L.P.'s Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World
Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Update - MarketBeat
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update - The Manila Times
Korro Bio Launches First Clinical Trial for AATD Treatment KRRO-110, Marks Clinical Stage Milestone - StockTitan
Korro Bio (NASDAQ:KRRO) Research Coverage Started at Oppenheimer - Defense World
Korro Bio (NASDAQ:KRRO) Now Covered by Analysts at Oppenheimer - MarketBeat
Korro Bio CEO to Present RNA Editing Breakthroughs at JP Morgan Healthcare Conference - StockTitan
Geode Capital Management LLC Sells 2,161 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Stock Position Increased by State Street Corp - MarketBeat
State Street Corp Acquires 18,877 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio: Still Too Long To Go… Just Keep Watching For Now (Rating Upgrade) (NASDAQ:KRRO) - Seeking Alpha
Wellington Management Group LLP Invests $436,000 in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Frequency Therapeutics : The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors - Marketscreener.com
BNP Paribas Financial Markets Purchases 4,470 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical catalyst - Investing.com Nigeria
Fmr LLC Has $19.37 Million Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Why Korro Bio (KRRO) Should Be on Your Investment Radar - Nasdaq
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
100-employee biotech opens new Kendall Square HQ - The Business Journals
Verition Fund Management LLC Has $3.12 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 6.5% in November - Defense World
Quest Partners LLC Has $59,000 Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Eventide Asset Management LLC Sells 137,989 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully - Simply Wall St
Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com
HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat
Korro Bio Inc Azioni (KRRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Korro Bio Inc Azioni (KRRO) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):